Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Natalizumab Therapy for Multiple Sclerosis

(2013) Jeremy Chataway et al.   Neurotherapeutics

Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review

(2012) E. Lu et al.   NEUROLOGY

Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis

(2011) A. Bayas et al.   ACTA NEUROLOGICA SCANDINAVICA

Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment

(2011) Kerstin Hellwig et al.   Multiple Sclerosis Journal

Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor

(2009) Nancy G. Wehner et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor

(2009) Nancy G. Wehner et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Effects of natalizumab, an α4 integrin inhibitor, on the development of Hartley guinea pigs

(2009) Nancy G. Wehner et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Immunotoxicity profile of natalizumab

(2009) Nancy G. Wehner et al.   Journal of Immunotoxicology

Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis

(2008) J. Dahl et al.   JOURNAL OF NEUROLOGY